Utilization trends and safety of intravenous iron replacement in pediatric specialty care: A large retrospective cohort study

Iron deficiency is a common and clinically diverse hematologic disorder in childhood for which oral iron is often an infeasible or ineffective treatment option. Intravenous (IV) iron can be an efficient and highly successful means of iron replacement but its use has not been well‐characterized on a large scale in pediatrics.

[1]  I. Macdougall,et al.  The available intravenous iron formulations: History, efficacy, and toxicology , 2017, Hemodialysis international. International Symposium on Home Hemodialysis.

[2]  J. Powers,et al.  Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Who Respond Poorly to Oral Iron , 2017, The Journal of pediatrics.

[3]  I. Dankó,et al.  Correction of Iron Deficiency Anemia With Intravenous Iron Sucrose in Children With Inflammatory Bowel Disease , 2016, Journal of pediatric gastroenterology and nutrition.

[4]  D. Graham,et al.  Risk of Anaphylaxis With Intravenous Iron Products. , 2016, JAMA.

[5]  E. Mantadakis Advances in Pediatric Intravenous Iron Therapy , 2016, Pediatric blood & cancer.

[6]  E. Mantadakis,et al.  Parenteral iron therapy in children with iron deficiency anemia , 2015, World Journal of Pediatrics.

[7]  E. Mantadakis,et al.  Intravenous iron sucrose for children with iron deficiency anemia: a single institution study , 2016, World Journal of Pediatrics.

[8]  Mark S Levenson,et al.  Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products. , 2015, JAMA.

[9]  J. Adamson,et al.  On the safety of intravenous iron, evidence trumps conjecture , 2015, Haematologica.

[10]  J. Sloan,et al.  Iron-Deficiency Anemia. , 2015, The New England journal of medicine.

[11]  G. Virgin,et al.  Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases , 2014, BMC Gastroenterology.

[12]  A. Bircher,et al.  Hypersensitivity from intravenous iron products. , 2014, Immunology and allergy clinics of North America.

[13]  T. McCavit,et al.  Intravenous low molecular weight iron dextran in children with iron deficiency anemia unresponsive to oral iron , 2013, Pediatric blood & cancer.

[14]  Robert T. Means,et al.  Iron deficiency anemia , 2013, Hematology.

[15]  G. Buchanan,et al.  Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy , 2012 .

[16]  S. Rajasekaran,et al.  Ferumoxytol Infusion in Pediatric Patients with Gastrointestinal Disorders: First Case Series , 2011, The Annals of pharmacotherapy.

[17]  M. Georgieff Long-term brain and behavioral consequences of early iron deficiency. , 2011, Nutrition reviews.

[18]  G. Buchanan,et al.  Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy , 2011, Pediatric blood & cancer.

[19]  M. Auerbach,et al.  Clinical use of intravenous iron: administration, efficacy, and safety. , 2010, Hematology. American Society of Hematology. Education Program.

[20]  R. Baker,et al.  Diagnosis and Prevention of Iron Deficiency and Iron-Deficiency Anemia in Infants and Young Children (0–3 Years of Age) , 2010, Pediatrics.

[21]  John Jonides,et al.  Iron deficiency in infancy and neurocognitive functioning at 19 years: evidence of long-term deficits in executive function and recognition memory , 2010, Nutritional neuroscience.

[22]  N. Kaciroti,et al.  Preschool-aged children with iron deficiency anemia show altered affect and behavior. , 2007, The Journal of nutrition.

[23]  M. Sipahioğlu,et al.  Is There a Difference between the Allergic Potencies of the Iron Sucrose and Low Molecular Weight Iron Dextran? , 2007, Renal failure.

[24]  A. Bousvaros,et al.  Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation , 2006, Inflammatory bowel diseases.

[25]  G. Rodgers,et al.  Parenteral iron therapy: a single institution's experience over a 5-year period. , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

[26]  G. Aronoff Safety of intravenous iron in clinical practice: implications for anemia management protocols. , 2004, Journal of the American Society of Nephrology : JASN.

[27]  G. Rodgers,et al.  Parenteral iron therapy options , 2004, American journal of hematology.

[28]  S. Fishbane,et al.  The Comparative Safety of Intravenous Iron Dextran, Iron Saccharate, and Sodium Ferric Gluconate , 2000, Seminars in dialysis.

[29]  G. Faich,et al.  Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.